Should I buy or sell Precision BioSciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DTIL shares. View DTIL analyst ratings or view top-rated stocks .

What is Precision BioSciences' stock price target for 2024?

3 analysts have issued 1 year price targets for Precision BioSciences' shares. Their DTIL share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 681.3% from the stock's current price. View analysts price targets for DTIL or view top-rated stocks among Wall Street analysts .

How have DTIL shares performed in 2024?

Precision BioSciences' stock was trading at $0.3650 on January 1st, 2024. Since then, DTIL stock has increased by 5.2% and is now trading at $0.3840. View the best growth stocks for 2024 here .

When is Precision BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our DTIL earnings forecast .

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.40. The company had revenue of $24.04 million for the quarter, compared to analysts' expectations of $8.54 million. Precision BioSciences had a negative trailing twelve-month return on equity of 189.47% and a negative net margin of 140.60%. During the same period last year, the business posted ($0.50) EPS.

What ETF holds Precision BioSciences' stock ?

Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.

When did Precision BioSciences' stock split?

Precision BioSciences's stock reverse split on the morning of Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com . Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT) , Sorrento Therapeutics (SRNE) , Alector (ALEC) , Kaleido Biosciences (KLDO) , Gossamer Bio (GOSS) , Micron Technology (MU) , Homology Medicines (FIXX) , Heron Therapeutics (HRTX) , Inovio Pharmaceuticals (INO) and Invitae (NVTA) .

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Corient Private Wealth LLC (0.19%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alan List, Dario Scimeca, David S Thomson, David S Thomson , Derek Jantz , John Alexander Kelly, Matthew R Kane, Matthew R Kane , Michael Amoroso and Vince Craig Hopkin. View institutional ownership trends .

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Price, News & Analysis

$0.38

-0.02 (-3.95%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $0.37
▼
$0.39
50-Day Range: $0.35
▼
$0.44
52-Week Range: $0.28
▼
$1.29

Volume: 1.64 million shs
Average Volume: 2.41 million shs
Market Capitalization: $46.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Get Precision BioSciences alerts:

Precision BioSciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 681.3% Upside
$3.00 Price Target
Short Interest: Healthy
2.22% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.99
Upright™ Environmental Score
News Sentiment: 0.24
Based on 6 Articles This Week
Insider Trading: Selling Shares
$64,873 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.29) to ($0.21) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.13 out of 5 stars

Medical Sector

169th out of 922 stocks

Biological Products, Except Diagnostic Industry

26th out of 151 stocks

3.3

Analyst's Opinion

Consensus Rating
Precision BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Precision BioSciences has a forecasted upside of 681.3% from its current price of $0.38.
Amount of Analyst Coverage
Precision BioSciences has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.22% of the float of Precision BioSciences has been sold short.
Short Interest Ratio / Days to Cover
Precision BioSciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Precision BioSciences has recently increased by 458.15%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Precision BioSciences does not currently pay a dividend.
Dividend Growth
Precision BioSciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Precision BioSciences has received a 72.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.
Environmental Sustainability
The Environmental Impact score for Precision BioSciences is -0.99.

1.8

News and Social Media Coverage

News Sentiment
Precision BioSciences has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Precision BioSciences this week, compared to 4 articles on an average week.
Search Interest
Only 10 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Precision BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,873.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Precision BioSciences is held by insiders.
Percentage Held by Institutions
Only 37.99% of the stock of Precision BioSciences is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Precision BioSciences are expected to grow in the coming year, from ($0.29) to ($0.21) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Precision BioSciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Precision BioSciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Precision BioSciences has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Precision BioSciences Stock (NASDAQ:DTIL)

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

DTIL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DTIL Stock News Headlines

February 12, 2024 | americanbankingnews.com

Precision BioSciences Stock Scheduled to Reverse Split on Wednesday, February 14th (NASDAQ:DTIL)

February 9, 2024 | markets.businessinsider.com

Precision BioScience Announces 1-For-30 Reverse Stock Split

February 12, 2024 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

February 6, 2024 | tmcnet.com

Precision Optical Technologies Announces General Availability of its Highly Anticipated Passive Optical Network Access Solution -- OpenPath™

February 5, 2024 | finance.yahoo.com

Rapid Growth Anticipated in Asia Pacific Precision Fermentation Ingredients Market

February 2, 2024 | sports.yahoo.com

Bucs QB Baker Mayfield wins Pro Bowl Precision Passing event

January 20, 2024 | msn.com

Precision BioSciences Stockholders Approve Reverse Split

January 10, 2024 | bizjournals.com

North Carolina biotechs ink potential $300M deal for cell therapy program

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

January 9, 2024 | msn.com

Why Precision BioSciences Stock Is Up Today

January 9, 2024 | markets.businessinsider.com

Precision BioSciences In Deal With TG Therapeutics On Cell Therapy Azer-cel

January 9, 2024 | msn.com

Precision BioSciences stock rises on $17.5M license deal with TG Therapeutic

January 9, 2024 | finance.yahoo.com

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

January 9, 2024 | finance.yahoo.com

TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

December 13, 2023 | finance.yahoo.com

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

December 4, 2023 | finance.yahoo.com

Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

November 30, 2023 | finance.yahoo.com

Precision BioSciences, Inc. (DTIL)

November 30, 2023 | finance.yahoo.com

Precision BioSciences to Present at Hep-DART 2023

November 28, 2023 | finance.yahoo.com

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

November 15, 2023 | markets.businessinsider.com

Promising Preclinical Results Support Buy Rating for Precision BioSciences’ cHBV Treatment Program

November 13, 2023 | finance.yahoo.com

Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

November 11, 2023 | benzinga.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Precision BioSciences, Inc. (NASDAQ: DTIL) and Encourages Investors to Contact the Firm

November 9, 2023 | markets.businessinsider.com

Advancing Gene Editing Pipeline and Potential Breakthrough in HBV Treatment Boost Precision BioSciences’ Buy Rating

November 9, 2023 | finance.yahoo.com

Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

November 8, 2023 | markets.businessinsider.com

Advancements in ARCUS Gene Editing Programs and Financial Stability Bolster Precision BioSciences’ Buy Rating

November 6, 2023 | benzinga.com

Earnings Outlook For Precision BioSciences

November 6, 2023 | msn.com

Precision BioSciences Q3 Earnings Preview

See More Headlines

Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 2/11/2024
Next Earnings (Estimated): 3/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:DTIL
CUSIP: N/A
CIK: 1357874
Web: www.precisionbiosciences.com
Phone: (919) 314-5512
Fax: N/A
Employees: 115
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $4.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +681.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-111,640,000.00
Net Margins: -140.60%
Pretax Margin: -164.10%
Return on Equity: -189.47%
Return on Assets: -39.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.88
Quick Ratio: 2.88

Sales & Book Value

Annual Sales: $25.10 million
Price / Sales: 1.87
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.54 per share
Price / Book: 0.71

Miscellaneous

Outstanding Shares: 121,920,000
Free Float: 115,701,000
Market Cap: $46.82 million
Optionable: Optionable
Beta: 1.41

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Michael Amoroso (Age 46)
President, CEO & Director
Comp: $979.04k
Mr. John Alexander Kelly R.Ph. (Age 57)
CFO & Principal Accounting Officer
Comp: $623.58k
Mr. Dario Scimeca (Age 48)
General Counsel & Secretary
Comp: $576.43k
Dr. Jefferson J. Smith Ph.D. (Age 51)
Co-Founder & Chief Research Officer
Mei Burris
Director of Investor Relations & Finance
Mr. Bruce Stevens
Vice President of Quality & Compliance
Maurissa Messier
Senior Director of Corporate Communications
Ms. Juli Blanche
Chief People Officer
Mr. Garrett Gincley
Head of Manufacturing
Dr. Alan F. List M.D. (Age 69)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DTIL Stock Analysis - Frequently Asked Questions

Should I buy or sell Precision BioSciences stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DTIL shares.
View DTIL analyst ratings or view top-rated stocks.
What is Precision BioSciences' stock price target for 2024?: 3 analysts have issued 1 year price targets for Precision BioSciences' shares. Their DTIL share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 681.3% from the stock's current price.
View analysts price targets for DTIL or view top-rated stocks among Wall Street analysts.
How have DTIL shares performed in 2024?: Precision BioSciences' stock was trading at $0.3650 on January 1st, 2024. Since then, DTIL stock has increased by 5.2% and is now trading at $0.3840.
View the best growth stocks for 2024 here.
When is Precision BioSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our DTIL earnings forecast.
How were Precision BioSciences' earnings last quarter?: Precision BioSciences, Inc. (NASDAQ:DTIL) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.40. The company had revenue of $24.04 million for the quarter, compared to analysts' expectations of $8.54 million. Precision BioSciences had a negative trailing twelve-month return on equity of 189.47% and a negative net margin of 140.60%. During the same period last year, the business posted ($0.50) EPS.
What ETF holds Precision BioSciences' stock ?: Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.

When did Precision BioSciences' stock split?: Precision BioSciences's stock reverse split on the morning of Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What is Matt Kane's approval rating as Precision BioSciences' CEO?: 12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Precision BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).
When did Precision BioSciences IPO?: (DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.
Who are Precision BioSciences' major shareholders?: Precision BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Corient Private Wealth LLC (0.19%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alan List, Dario Scimeca, David S Thomson, David S Thomson, Derek Jantz, John Alexander Kelly, Matthew R Kane, Matthew R Kane, Michael Amoroso and Vince Craig Hopkin.
View institutional ownership trends.
How do I buy shares of Precision BioSciences?: Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DTIL) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial